María Fernanda Martínez-Salazar1, Jesús Oaxaca-Navarro2, Alfonso Leija-Salas3, Sara García-Jiménez3, Miguel Angel Sánchez-Alemán4, Myrna Déciga-Campos1. 1. Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México. 2. CAPASITS Cuernavaca, Servicios de Salud del Estado de Morelos, Cuernavaca, Morelos, México. 3. Facultad de Farmacia, Universidad Autónoma del Estado de Morelos Cuernavaca, Morelos, México. 4. Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Abstract
OBJECTIVE: To analyse the most frequent self-reported adverse reactions (ARs), the durability and the causes of antiretrovirals (ARVs) regimens change, concomitant treatments and drug interactions related to the use of ARVs in a group of people living with HIV in Cuernavaca, Morelos, Mexico. MATERIALS AND METHODS: Cross-sectional study conducted in a clinic specialising in HIV 'CAPASITS-Cuernavaca' in Mexico from February to June 2015. People who wanted to participate were given a questionnaire on demographic characteristics, adherence, concomitant treatments and ARs. To understand the clinical variables, the clinical records were reviewed. Quantitative variables were compared using Student's t-test for normal data and the Mann-Whitney U test for non-normal data. For comparisons between categorical variables, the χ2 test was used. All tests used a significance level of 0.05. RESULTS: A total of 96 people participated, and 218 ARs (mean= 2.3±1.9) were found. The most frequently encountered ARs were dizziness (53.1%), insomnia (21.9%) and lucid dreams (17.7%). Twenty-three people (24%) were polymedicated, and 18 potential interactions were detected in 12 people. CONCLUSIONS: The results suggest that a thorough analysis of the possible drug interactions should be performed for polymedicated people on ARV treatment and that a protocol should be designed for the monitoring and management of AR to ensure a good adherence to ARV treatment.
OBJECTIVE: To analyse the most frequent self-reported adverse reactions (ARs), the durability and the causes of antiretrovirals (ARVs) regimens change, concomitant treatments and drug interactions related to the use of ARVs in a group of people living with HIV in Cuernavaca, Morelos, Mexico. MATERIALS AND METHODS: Cross-sectional study conducted in a clinic specialising in HIV 'CAPASITS-Cuernavaca' in Mexico from February to June 2015. People who wanted to participate were given a questionnaire on demographic characteristics, adherence, concomitant treatments and ARs. To understand the clinical variables, the clinical records were reviewed. Quantitative variables were compared using Student's t-test for normal data and the Mann-Whitney U test for non-normal data. For comparisons between categorical variables, the χ2 test was used. All tests used a significance level of 0.05. RESULTS: A total of 96 people participated, and 218 ARs (mean= 2.3±1.9) were found. The most frequently encountered ARs were dizziness (53.1%), insomnia (21.9%) and lucid dreams (17.7%). Twenty-three people (24%) were polymedicated, and 18 potential interactions were detected in 12 people. CONCLUSIONS: The results suggest that a thorough analysis of the possible drug interactions should be performed for polymedicated people on ARV treatment and that a protocol should be designed for the monitoring and management of AR to ensure a good adherence to ARV treatment.
Entities:
Keywords:
HIV; adverse reactions; antiretroviral; drug interactions; polymedication
Authors: A Ammassari; R Murri; P Pezzotti; M P Trotta; L Ravasio; P De Longis; S Lo Caputo; P Narciso; S Pauluzzi; G Carosi; S Nappa; P Piano; C M Izzo; M Lichtner; G Rezza; A Monforte; G Ippolito; M d'Arminio Moroni; A W Wu; A Antinori Journal: J Acquir Immune Defic Syndr Date: 2001-12-15 Impact factor: 3.731
Authors: David W Haas; Laura M Smeaton; Robert W Shafer; Gregory K Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victor De Gruttola; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; Alfred L George; John P Donahue; Richard B Kim Journal: J Infect Dis Date: 2005-11-01 Impact factor: 5.226
Authors: M M R de Maat; A de Boer; C H W Koks; J W Mulder; P L Meenhorst; E C M van Gorp; A T A Mairuhu; A D R Huitema; J H Beijnen Journal: J Clin Pharm Ther Date: 2004-04 Impact factor: 2.512
Authors: Laura Gratacòs; Montse Tuset; Carles Codina; José M Miró; Josep Mallolas; Núria Miserachs; Maria Teresa Martín-Conde; Elena del Cacho; Elisa de Lazzari; Josep Ribas; Josep M Gatell Journal: Med Clin (Barc) Date: 2006-02-25 Impact factor: 1.725
Authors: Cristiane A Menezes de Pádua; Cibele C César; Palmira F Bonolo; Francisco A Acurcio; Mark Drew C Guimarães Journal: Braz J Infect Dis Date: 2007-02 Impact factor: 1.949
Authors: Jeonnette R Ickovics; Ann Cameron; Robert Zackin; Roland Bassett; Margaret Chesney; Victoria A Johnson; Daniel R Kuritzkes Journal: Antivir Ther Date: 2002-09